In an October 2018, trial in West Virginia, a federal jury found that Boehringer Ingelheim Pharmaceuticals Inc. was not forthright about the risk of potential bleeding injuries with its drug, Pradaxa (Dabigatran). The jury awarded the plaintiff $250,000 for medical expenses and pain and suffering, as well as $1 million in punitive damages. This was the first trial win for plaintiffs, after the manufacturer had succeeded at three prior trials. Boehringer Ingelheim Pharmaceuticals, Inc. has appealed the verdict.

Continue Reading Pradaxa (Dabigatran) Trials Continue Nationwide

As we have previously reported, Boehringer Ingelheim, the manufacturer of Pradaxa, has been sanctioned during the course of the federal litigation for destroying relevant documents. In a recent Case Management Order, Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, revisited the manufacturer’s misconduct and fixed new sanctions.

In

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur

The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use.

Physicians and analysts have commented that the health risks associated with

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur